{"transactions":[{"id":322236,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":15085,"kind":"organization","name":"KKR Genetic Disorder L.P.","position":1,"cik":"0001780408","reported_name":"KKR Genetic Disorder L.P.","relationship":{"ten_percent_owner":true}},{"id":15086,"kind":"organization","name":"KKR Genetic Disorder GP LLC","position":2,"cik":"0001780428","reported_name":"KKR Genetic Disorder GP LLC","relationship":{"ten_percent_owner":true}},{"id":335,"kind":"organization","name":"KKR Group Partnership L.P.","position":3,"cik":"0001472698","reported_name":"KKR Group Partnership L.P.","relationship":{"ten_percent_owner":true}},{"id":336,"kind":"organization","name":"KKR Group Holdings Corp.","position":4,"cik":"0001743754","reported_name":"KKR Group Holdings Corp.","relationship":{"ten_percent_owner":true}},{"id":337,"kind":"organization","name":"KKR Group Co. Inc.","position":5,"cik":"0001932162","reported_name":"KKR Group Co. Inc.","relationship":{"ten_percent_owner":true}},{"id":338,"kind":"organization","name":"KKR & Co. Inc.","symbol":"KKR","position":6,"cik":"0001404912","reported_name":"KKR & Co. Inc.","relationship":{"ten_percent_owner":true}},{"id":339,"kind":"organization","name":"KKR Management LLP","position":7,"cik":"0001472694","reported_name":"KKR Management LLP","relationship":{"ten_percent_owner":true}},{"id":340,"kind":"person","name":"KRAVIS HENRY R","position":8,"cik":"0001081714","reported_name":"KRAVIS HENRY R","relationship":{"ten_percent_owner":true}},{"id":341,"kind":"person","name":"ROBERTS GEORGE R","position":9,"cik":"0001081715","reported_name":"ROBERTS GEORGE R","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2025-05-14T21:24:23.000Z","date":"2025-05-12","kind":"sale","planned":false,"acquired":false,"shares":6000000,"price":34.2,"value":205200000.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects the sale of 6,000,000 shares of common stock of BridgeBio Pharma, Inc. (the \"Issuer\"), par value $0.001 per share (the \"Common Stock\"), by KKR Genetic Disorder L.P. in a block sale at a price per share of $34.20 pursuant to Rule 144 of the Securities Act of 1933, as amended."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares of Common Stock are held by KKR Genetic Disorder L.P. KKR Genetic Disorder GP LLC is the general partner of KKR Genetic Disorder L.P. KKR Group Partnership L.P. is the sole member of KKR Genetic Disorder GP LLC. KKR Group Holdings Corp. is the general partner of KKR Group Partnership L.P. KKR Group Co. Inc. is the sole shareholder of KKR Group Holdings Corp. KKR & Co. Inc. is the sole shareholder of KKR Group Co. Inc. KKR Management LLP is the Series I preferred stockholder of KKR & Co. Inc. Messrs. Henry R. Kravis and George R. Roberts are the founding partners of KKR Management LLP but disclaim beneficial ownership of the reported securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein. The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the Reporting Persons are the beneficial owners of any securities reported herein."}],"balance_after":13260971,"source":{"system":"sec-edgar","filing":"0001140361-25-019003","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1081715/000114036125019003/form4.xml","form_type":"4"}},{"id":324412,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":15085,"kind":"organization","name":"KKR Genetic Disorder L.P.","position":1,"cik":"0001780408","reported_name":"KKR Genetic Disorder L.P.","relationship":{"ten_percent_owner":true}},{"id":15086,"kind":"organization","name":"KKR Genetic Disorder GP LLC","position":2,"cik":"0001780428","reported_name":"KKR Genetic Disorder GP LLC","relationship":{"ten_percent_owner":true}},{"id":335,"kind":"organization","name":"KKR Group Partnership L.P.","position":3,"cik":"0001472698","reported_name":"KKR Group Partnership L.P.","relationship":{"ten_percent_owner":true}},{"id":336,"kind":"organization","name":"KKR Group Holdings Corp.","position":4,"cik":"0001743754","reported_name":"KKR Group Holdings Corp.","relationship":{"ten_percent_owner":true}},{"id":337,"kind":"organization","name":"KKR Group Co. Inc.","position":5,"cik":"0001932162","reported_name":"KKR Group Co. Inc.","relationship":{"ten_percent_owner":true}},{"id":338,"kind":"organization","name":"KKR & Co. Inc.","symbol":"KKR","position":6,"cik":"0001404912","reported_name":"KKR & Co. Inc.","relationship":{"ten_percent_owner":true}},{"id":339,"kind":"organization","name":"KKR Management LLP","position":7,"cik":"0001472694","reported_name":"KKR Management LLP","relationship":{"ten_percent_owner":true}},{"id":340,"kind":"person","name":"KRAVIS HENRY R","position":8,"cik":"0001081714","reported_name":"KRAVIS HENRY R","relationship":{"ten_percent_owner":true}},{"id":341,"kind":"person","name":"ROBERTS GEORGE R","position":9,"cik":"0001081715","reported_name":"ROBERTS GEORGE R","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2025-03-07T23:09:03.000Z","date":"2025-03-05","kind":"sale","planned":false,"acquired":false,"shares":6000000,"price":32.96,"value":197760000.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects the sale of 6,000,000 shares of common stock of BridgeBio Pharma, Inc. (the \"Issuer\"), par value $0.001 per share (the \"Common Stock\"), by KKR Genetic Disorder L.P. in a block sale at a price per share of $32.96 pursuant to Rule 144 of the Securities Act of 1933, as amended."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares of Common Stock are held by KKR Genetic Disorder L.P. KKR Genetic Disorder GP LLC is the general partner of KKR Genetic Disorder L.P. KKR Group Partnership L.P. is the sole member of KKR Genetic Disorder GP LLC. KKR Group Holdings Corp. is the general partner of KKR Group Partnership L.P. KKR Group Co. Inc. is the sole shareholder of KKR Group Holdings Corp. KKR & Co. Inc. is the sole shareholder of KKR Group Co. Inc. KKR Management LLP is the Series I preferred stockholder of KKR & Co. Inc. Messrs. Henry R. Kravis and George R. Roberts are the founding partners of KKR Management LLP but disclaim beneficial ownership of the reported securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein. The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the Reporting Persons are the beneficial owners of any securities reported herein."}],"balance_after":19260971,"source":{"system":"sec-edgar","filing":"0001140361-25-007699","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1081715/000114036125007699/form4.xml","form_type":"4"}},{"id":330649,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":15085,"kind":"organization","name":"KKR Genetic Disorder L.P.","position":1,"cik":"0001780408","reported_name":"KKR Genetic Disorder L.P.","relationship":{"ten_percent_owner":true}},{"id":15086,"kind":"organization","name":"KKR Genetic Disorder GP LLC","position":2,"cik":"0001780428","reported_name":"KKR Genetic Disorder GP LLC","relationship":{"ten_percent_owner":true}},{"id":335,"kind":"organization","name":"KKR Group Partnership L.P.","position":3,"cik":"0001472698","reported_name":"KKR Group Partnership L.P.","relationship":{"ten_percent_owner":true}},{"id":336,"kind":"organization","name":"KKR Group Holdings Corp.","position":4,"cik":"0001743754","reported_name":"KKR Group Holdings Corp.","relationship":{"ten_percent_owner":true}},{"id":337,"kind":"organization","name":"KKR Group Co. Inc.","position":5,"cik":"0001932162","reported_name":"KKR Group Co. Inc.","relationship":{"ten_percent_owner":true}},{"id":338,"kind":"organization","name":"KKR & Co. Inc.","symbol":"KKR","position":6,"cik":"0001404912","reported_name":"KKR & Co. Inc.","relationship":{"ten_percent_owner":true}},{"id":339,"kind":"organization","name":"KKR Management LLP","position":7,"cik":"0001472694","reported_name":"KKR Management LLP","relationship":{"ten_percent_owner":true}},{"id":340,"kind":"person","name":"KRAVIS HENRY R","position":8,"cik":"0001081714","reported_name":"KRAVIS HENRY R","relationship":{"ten_percent_owner":true}},{"id":341,"kind":"person","name":"ROBERTS GEORGE R","position":9,"cik":"0001081715","reported_name":"ROBERTS GEORGE R","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2024-09-17T22:44:33.000Z","date":"2024-09-13","kind":"sale","planned":false,"acquired":false,"shares":5800000,"price":25.75,"value":149350000.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects the sale of 5,800,000 shares of common stock of BridgeBio Pharma, Inc. (the \"Issuer\"), par value $0.001 per share (the \"Common Stock\"), by KKR Genetic Disorder L.P. in a block sale at a price per share of $25.75 pursuant to Rule 144 of the Securities Act of 1933, as amended."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares of Common Stock are held by KKR Genetic Disorder L.P. KKR Genetic Disorder GP LLC is the general partner of KKR Genetic Disorder L.P. KKR Group Partnership L.P. is the sole member of KKR Genetic Disorder GP LLC. KKR Group Holdings Corp. is the general partner of KKR Group Partnership L.P. KKR Group Co. Inc. is the sole shareholder of KKR Group Holdings Corp. KKR & Co. Inc. is the sole shareholder of KKR Group Co. Inc. KKR Management LLP is the Series I preferred stockholder of KKR & Co. Inc. Messrs. Henry R. Kravis and George R. Roberts are the founding partners of KKR Management LLP but disclaim beneficial ownership of the reported securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein. The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the Reporting Persons are the beneficial owners of any securities reported herein."}],"balance_after":25260971,"source":{"system":"sec-edgar","filing":"0001140361-24-041329","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1081715/000114036124041329/form4.xml","form_type":"4"}},{"id":380112,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":15085,"kind":"organization","name":"KKR Genetic Disorder L.P.","position":1,"cik":"0001780408","reported_name":"KKR Genetic Disorder L.P.","relationship":{"ten_percent_owner":true}},{"id":15086,"kind":"organization","name":"KKR Genetic Disorder GP LLC","position":2,"cik":"0001780428","reported_name":"KKR Genetic Disorder GP LLC","relationship":{"ten_percent_owner":true}},{"id":335,"kind":"organization","name":"KKR Group Partnership L.P.","position":3,"cik":"0001472698","reported_name":"KKR Group Partnership L.P.","relationship":{"ten_percent_owner":true}},{"id":336,"kind":"organization","name":"KKR Group Holdings Corp.","position":4,"cik":"0001743754","reported_name":"KKR Group Holdings Corp.","relationship":{"ten_percent_owner":true}},{"id":338,"kind":"organization","name":"KKR & Co. Inc.","symbol":"KKR","position":5,"cik":"0001404912","reported_name":"KKR & Co. Inc.","relationship":{"ten_percent_owner":true}},{"id":339,"kind":"organization","name":"KKR Management LLP","position":6,"cik":"0001472694","reported_name":"KKR Management LLP","relationship":{"ten_percent_owner":true}},{"id":340,"kind":"person","name":"KRAVIS HENRY R","position":7,"cik":"0001081714","reported_name":"KRAVIS HENRY R","relationship":{"ten_percent_owner":true}},{"id":341,"kind":"person","name":"ROBERTS GEORGE R","position":8,"cik":"0001081715","reported_name":"ROBERTS GEORGE R","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2021-02-17T22:36:17.000Z","date":"2021-02-17","kind":"sale","acquired":false,"shares":3450000,"price":60.4688,"value":208617360.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This amount represents the $62.50 secondary public offering price per share of common stock of BridgeBio Pharma, Inc. (\"Common Stock\") less the underwriting discount of $2.03125 per share for shares sold pursuant to an underwritten public offering"},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"This amount represents the $62.50 secondary public offering price per share of common stock of BridgeBio Pharma, Inc. (\"Common Stock\") less the underwriting discount of $2.03125 per share for shares sold pursuant to an underwritten public offering"},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities of the Issuer are held by KKR Genetic Disorder L.P. KKR Genetic Disorder GP LLC, as the general partner of KKR Genetic Disorder L.P., KKR Group Partnership L.P., as the sole member of KKR Genetic Disorder GP LLC, KKR Group Holdings Corp., as the general partner of KKR Group Partnership L.P., KKR & Co. Inc., as the sole shareholder of KKR Group Holdings Corp., KKR Management LLP, as the Series I preferred stockholder of KKR & Co. Inc., and Messrs. Henry R. Kravis and George R. Roberts, as the founding partners of KKR Management LLP, may be deemed to be the beneficial owners having shared voting and investment power with respect to the shares described above. Each of Messrs. Kravis and Roberts disclaims beneficial ownership of the shares held by KKR Genetic Disorder L.P."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein. The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the Reporting Persons are the beneficial owners of any securities reported herein."}],"balance_after":31060971,"source":{"system":"sec-edgar","filing":"0001140361-21-005267","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1081715/000114036121005267/form4.xml","form_type":"4"}},{"id":389966,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":15085,"kind":"organization","name":"KKR Genetic Disorder L.P.","position":1,"cik":"0001780408","reported_name":"KKR Genetic Disorder L.P.","relationship":{"ten_percent_owner":true}},{"id":15086,"kind":"organization","name":"KKR Genetic Disorder GP LLC","position":2,"cik":"0001780428","reported_name":"KKR Genetic Disorder GP LLC","relationship":{"ten_percent_owner":true}},{"id":335,"kind":"organization","name":"KKR Group Partnership L.P.","position":3,"cik":"0001472698","reported_name":"KKR Group Partnership L.P.","relationship":{"ten_percent_owner":true}},{"id":336,"kind":"organization","name":"KKR Group Holdings Corp.","position":4,"cik":"0001743754","reported_name":"KKR Group Holdings Corp.","relationship":{"ten_percent_owner":true}},{"id":338,"kind":"organization","name":"KKR & Co. Inc.","symbol":"KKR","position":5,"cik":"0001404912","reported_name":"KKR & Co. Inc.","relationship":{"ten_percent_owner":true}},{"id":339,"kind":"organization","name":"KKR Management LLP","position":6,"cik":"0001472694","reported_name":"KKR Management LLP","relationship":{"ten_percent_owner":true}},{"id":340,"kind":"person","name":"KRAVIS HENRY R","position":7,"cik":"0001081714","reported_name":"KRAVIS HENRY R","relationship":{"ten_percent_owner":true}},{"id":341,"kind":"person","name":"ROBERTS GEORGE R","position":8,"cik":"0001081715","reported_name":"ROBERTS GEORGE R","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2020-06-01T21:15:21.000Z","date":"2020-05-28","kind":"sale","acquired":false,"shares":2389690,"price":33.39,"value":79791749.1,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities of the Issuer are held by KKR Genetic Disorder L.P. KKR Genetic Disorder GP LLC, as the general partner of KKR Genetic Disorder L.P., KKR Group Partnership L.P., as the sole member of KKR Genetic Disorder GP LLC, KKR Group Holdings Corp., as the general partner of KKR Group Partnership L.P., KKR & Co. Inc., as the sole shareholder of KKR Group Holdings Corp., KKR Management LLP, as the Series I preferred stockholder of KKR & Co. Inc., and Messrs. Henry R. Kravis and George R. Roberts, as the founding partners of KKR Management LLP, may be deemed to be the beneficial owners having shared voting and investment power with respect to the shares described above. Each of Messrs. Kravis and Roberts disclaims beneficial ownership of the shares held by KKR Genetic Disorder L.P."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein. The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the Reporting Persons are the beneficial owners of any securities reported herein."}],"balance_after":34510971,"source":{"system":"sec-edgar","filing":"0001140361-20-012852","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1081715/000114036120012852/form4.xml","form_type":"4"}},{"id":401655,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":15085,"kind":"organization","name":"KKR Genetic Disorder L.P.","position":1,"cik":"0001780408","reported_name":"KKR Genetic Disorder L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":341,"kind":"person","name":"ROBERTS GEORGE R","position":2,"cik":"0001081715","reported_name":"ROBERTS GEORGE R","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":340,"kind":"person","name":"KRAVIS HENRY R","position":3,"cik":"0001081714","reported_name":"KRAVIS HENRY R","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":339,"kind":"organization","name":"KKR Management LLP","position":4,"cik":"0001472694","reported_name":"KKR Management LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":338,"kind":"organization","name":"KKR & Co. Inc.","symbol":"KKR","position":5,"cik":"0001404912","reported_name":"KKR & Co. Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":336,"kind":"organization","name":"KKR Group Holdings Corp.","position":6,"cik":"0001743754","reported_name":"KKR Group Holdings Corp.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15930,"kind":"organization","name":"KKR Management Holdings Corp","position":7,"cik":"0001472692","reported_name":"KKR Management Holdings Corp","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15931,"kind":"organization","name":"KKR Management Holdings L.P.","position":8,"cik":"0001472693","reported_name":"KKR Management Holdings L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15086,"kind":"organization","name":"KKR Genetic Disorder GP LLC","position":9,"cik":"0001780428","reported_name":"KKR Genetic Disorder GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series D Preferred Units","published_at":"2019-07-03T20:30:24.000Z","date":"2019-07-01","kind":"exercise","acquired":false,"shares":50446451,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering (the \"IPO\"), all Series B Preferred Units, Series C Preferred Units and Series D Preferred Units (collectively, the \"Preferred Units\") of BridgeBio Pharma LLC (the \"LLC\") were exchanged for shares of Common Stock, par value $0.001 per share (the \"Common Stock\"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the \"Reorganization\"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of Preferred Units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, with a value implied by the IPO price of $17.00 per share. The Preferred Units had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering (the \"IPO\"), all Series B Preferred Units, Series C Preferred Units and Series D Preferred Units (collectively, the \"Preferred Units\") of BridgeBio Pharma LLC (the \"LLC\") were exchanged for shares of Common Stock, par value $0.001 per share (the \"Common Stock\"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the \"Reorganization\"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of Preferred Units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, with a value implied by the IPO price of $17.00 per share. The Preferred Units had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering (the \"IPO\"), all Series B Preferred Units, Series C Preferred Units and Series D Preferred Units (collectively, the \"Preferred Units\") of BridgeBio Pharma LLC (the \"LLC\") were exchanged for shares of Common Stock, par value $0.001 per share (the \"Common Stock\"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the \"Reorganization\"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of Preferred Units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, with a value implied by the IPO price of $17.00 per share. The Preferred Units had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering (the \"IPO\"), all Series B Preferred Units, Series C Preferred Units and Series D Preferred Units (collectively, the \"Preferred Units\") of BridgeBio Pharma LLC (the \"LLC\") were exchanged for shares of Common Stock, par value $0.001 per share (the \"Common Stock\"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the \"Reorganization\"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of Preferred Units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, with a value implied by the IPO price of $17.00 per share. The Preferred Units had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities of the Issuer are held by KKR Genetic Disorder L.P. KKR Genetic Disorder GP LLC, as the general partner of KKR Genetic Disorder L.P., KKR Management Holdings L.P., as the sole member of KKR Genetic Disorder GP LLC, KKR Management Holdings Corp., as the general partner of KKR Management Holdings L.P., KKR Group Holdings Corp., as the sole shareholder of KKR Management Holdings Corp., KKR & Co. Inc., as the sole shareholder of KKR Group Holdings Corp., KKR Management LLC, as the Class B common stockholder of KKR & Co. Inc., and Messrs. Henry R. Kravis and George R. Roberts, as the designated members of KKR Management LLC, may be deemed to be the beneficial owners having shared voting and investment power with respect to the shares described above. Each of Messrs. Kravis and Roberts disclaims beneficial ownership of the shares held by KKR Genetic Disorder L.P."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein. The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the Reporting Persons are the beneficial owners of any securities reported herein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":10178954},"source":{"system":"sec-edgar","filing":"0000899243-19-019173","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1081715/000089924319019173/doc4.xml","form_type":"4"}},{"id":401654,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":15085,"kind":"organization","name":"KKR Genetic Disorder L.P.","position":1,"cik":"0001780408","reported_name":"KKR Genetic Disorder L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":341,"kind":"person","name":"ROBERTS GEORGE R","position":2,"cik":"0001081715","reported_name":"ROBERTS GEORGE R","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":340,"kind":"person","name":"KRAVIS HENRY R","position":3,"cik":"0001081714","reported_name":"KRAVIS HENRY R","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":339,"kind":"organization","name":"KKR Management LLP","position":4,"cik":"0001472694","reported_name":"KKR Management LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":338,"kind":"organization","name":"KKR & Co. Inc.","symbol":"KKR","position":5,"cik":"0001404912","reported_name":"KKR & Co. Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":336,"kind":"organization","name":"KKR Group Holdings Corp.","position":6,"cik":"0001743754","reported_name":"KKR Group Holdings Corp.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15930,"kind":"organization","name":"KKR Management Holdings Corp","position":7,"cik":"0001472692","reported_name":"KKR Management Holdings Corp","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15931,"kind":"organization","name":"KKR Management Holdings L.P.","position":8,"cik":"0001472693","reported_name":"KKR Management Holdings L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15086,"kind":"organization","name":"KKR Genetic Disorder GP LLC","position":9,"cik":"0001780428","reported_name":"KKR Genetic Disorder GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Units","published_at":"2019-07-03T20:30:24.000Z","date":"2019-07-01","kind":"exercise","acquired":false,"shares":36246893,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering (the \"IPO\"), all Series B Preferred Units, Series C Preferred Units and Series D Preferred Units (collectively, the \"Preferred Units\") of BridgeBio Pharma LLC (the \"LLC\") were exchanged for shares of Common Stock, par value $0.001 per share (the \"Common Stock\"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the \"Reorganization\"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of Preferred Units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, with a value implied by the IPO price of $17.00 per share. The Preferred Units had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering (the \"IPO\"), all Series B Preferred Units, Series C Preferred Units and Series D Preferred Units (collectively, the \"Preferred Units\") of BridgeBio Pharma LLC (the \"LLC\") were exchanged for shares of Common Stock, par value $0.001 per share (the \"Common Stock\"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the \"Reorganization\"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of Preferred Units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, with a value implied by the IPO price of $17.00 per share. The Preferred Units had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering (the \"IPO\"), all Series B Preferred Units, Series C Preferred Units and Series D Preferred Units (collectively, the \"Preferred Units\") of BridgeBio Pharma LLC (the \"LLC\") were exchanged for shares of Common Stock, par value $0.001 per share (the \"Common Stock\"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the \"Reorganization\"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of Preferred Units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, with a value implied by the IPO price of $17.00 per share. The Preferred Units had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering (the \"IPO\"), all Series B Preferred Units, Series C Preferred Units and Series D Preferred Units (collectively, the \"Preferred Units\") of BridgeBio Pharma LLC (the \"LLC\") were exchanged for shares of Common Stock, par value $0.001 per share (the \"Common Stock\"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the \"Reorganization\"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of Preferred Units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, with a value implied by the IPO price of $17.00 per share. The Preferred Units had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities of the Issuer are held by KKR Genetic Disorder L.P. KKR Genetic Disorder GP LLC, as the general partner of KKR Genetic Disorder L.P., KKR Management Holdings L.P., as the sole member of KKR Genetic Disorder GP LLC, KKR Management Holdings Corp., as the general partner of KKR Management Holdings L.P., KKR Group Holdings Corp., as the sole shareholder of KKR Management Holdings Corp., KKR & Co. Inc., as the sole shareholder of KKR Group Holdings Corp., KKR Management LLC, as the Class B common stockholder of KKR & Co. Inc., and Messrs. Henry R. Kravis and George R. Roberts, as the designated members of KKR Management LLC, may be deemed to be the beneficial owners having shared voting and investment power with respect to the shares described above. Each of Messrs. Kravis and Roberts disclaims beneficial ownership of the shares held by KKR Genetic Disorder L.P."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein. The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the Reporting Persons are the beneficial owners of any securities reported herein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":8215295},"source":{"system":"sec-edgar","filing":"0000899243-19-019173","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1081715/000089924319019173/doc4.xml","form_type":"4"}},{"id":401653,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":15085,"kind":"organization","name":"KKR Genetic Disorder L.P.","position":1,"cik":"0001780408","reported_name":"KKR Genetic Disorder L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":341,"kind":"person","name":"ROBERTS GEORGE R","position":2,"cik":"0001081715","reported_name":"ROBERTS GEORGE R","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":340,"kind":"person","name":"KRAVIS HENRY R","position":3,"cik":"0001081714","reported_name":"KRAVIS HENRY R","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":339,"kind":"organization","name":"KKR Management LLP","position":4,"cik":"0001472694","reported_name":"KKR Management LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":338,"kind":"organization","name":"KKR & Co. Inc.","symbol":"KKR","position":5,"cik":"0001404912","reported_name":"KKR & Co. Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":336,"kind":"organization","name":"KKR Group Holdings Corp.","position":6,"cik":"0001743754","reported_name":"KKR Group Holdings Corp.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15930,"kind":"organization","name":"KKR Management Holdings Corp","position":7,"cik":"0001472692","reported_name":"KKR Management Holdings Corp","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15931,"kind":"organization","name":"KKR Management Holdings L.P.","position":8,"cik":"0001472693","reported_name":"KKR Management Holdings L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15086,"kind":"organization","name":"KKR Genetic Disorder GP LLC","position":9,"cik":"0001780428","reported_name":"KKR Genetic Disorder GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Units","published_at":"2019-07-03T20:30:24.000Z","date":"2019-07-01","kind":"exercise","acquired":false,"shares":81022727,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering (the \"IPO\"), all Series B Preferred Units, Series C Preferred Units and Series D Preferred Units (collectively, the \"Preferred Units\") of BridgeBio Pharma LLC (the \"LLC\") were exchanged for shares of Common Stock, par value $0.001 per share (the \"Common Stock\"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the \"Reorganization\"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of Preferred Units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, with a value implied by the IPO price of $17.00 per share. The Preferred Units had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering (the \"IPO\"), all Series B Preferred Units, Series C Preferred Units and Series D Preferred Units (collectively, the \"Preferred Units\") of BridgeBio Pharma LLC (the \"LLC\") were exchanged for shares of Common Stock, par value $0.001 per share (the \"Common Stock\"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the \"Reorganization\"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of Preferred Units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, with a value implied by the IPO price of $17.00 per share. The Preferred Units had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering (the \"IPO\"), all Series B Preferred Units, Series C Preferred Units and Series D Preferred Units (collectively, the \"Preferred Units\") of BridgeBio Pharma LLC (the \"LLC\") were exchanged for shares of Common Stock, par value $0.001 per share (the \"Common Stock\"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the \"Reorganization\"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of Preferred Units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, with a value implied by the IPO price of $17.00 per share. The Preferred Units had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering (the \"IPO\"), all Series B Preferred Units, Series C Preferred Units and Series D Preferred Units (collectively, the \"Preferred Units\") of BridgeBio Pharma LLC (the \"LLC\") were exchanged for shares of Common Stock, par value $0.001 per share (the \"Common Stock\"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the \"Reorganization\"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of Preferred Units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, with a value implied by the IPO price of $17.00 per share. The Preferred Units had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities of the Issuer are held by KKR Genetic Disorder L.P. KKR Genetic Disorder GP LLC, as the general partner of KKR Genetic Disorder L.P., KKR Management Holdings L.P., as the sole member of KKR Genetic Disorder GP LLC, KKR Management Holdings Corp., as the general partner of KKR Management Holdings L.P., KKR Group Holdings Corp., as the sole shareholder of KKR Management Holdings Corp., KKR & Co. Inc., as the sole shareholder of KKR Group Holdings Corp., KKR Management LLC, as the Class B common stockholder of KKR & Co. Inc., and Messrs. Henry R. Kravis and George R. Roberts, as the designated members of KKR Management LLC, may be deemed to be the beneficial owners having shared voting and investment power with respect to the shares described above. Each of Messrs. Kravis and Roberts disclaims beneficial ownership of the shares held by KKR Genetic Disorder L.P."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein. The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the Reporting Persons are the beneficial owners of any securities reported herein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":15859312},"source":{"system":"sec-edgar","filing":"0000899243-19-019173","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1081715/000089924319019173/doc4.xml","form_type":"4"}},{"id":401652,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":15085,"kind":"organization","name":"KKR Genetic Disorder L.P.","position":1,"cik":"0001780408","reported_name":"KKR Genetic Disorder L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":341,"kind":"person","name":"ROBERTS GEORGE R","position":2,"cik":"0001081715","reported_name":"ROBERTS GEORGE R","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":340,"kind":"person","name":"KRAVIS HENRY R","position":3,"cik":"0001081714","reported_name":"KRAVIS HENRY R","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":339,"kind":"organization","name":"KKR Management LLP","position":4,"cik":"0001472694","reported_name":"KKR Management LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":338,"kind":"organization","name":"KKR & Co. Inc.","symbol":"KKR","position":5,"cik":"0001404912","reported_name":"KKR & Co. Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":336,"kind":"organization","name":"KKR Group Holdings Corp.","position":6,"cik":"0001743754","reported_name":"KKR Group Holdings Corp.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15930,"kind":"organization","name":"KKR Management Holdings Corp","position":7,"cik":"0001472692","reported_name":"KKR Management Holdings Corp","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15931,"kind":"organization","name":"KKR Management Holdings L.P.","position":8,"cik":"0001472693","reported_name":"KKR Management Holdings L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15086,"kind":"organization","name":"KKR Genetic Disorder GP LLC","position":9,"cik":"0001780428","reported_name":"KKR Genetic Disorder GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-07-03T20:30:24.000Z","date":"2019-07-01","kind":"purchase","acquired":true,"shares":2647100,"price":17,"value":45000700.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities of the Issuer are held by KKR Genetic Disorder L.P. KKR Genetic Disorder GP LLC, as the general partner of KKR Genetic Disorder L.P., KKR Management Holdings L.P., as the sole member of KKR Genetic Disorder GP LLC, KKR Management Holdings Corp., as the general partner of KKR Management Holdings L.P., KKR Group Holdings Corp., as the sole shareholder of KKR Management Holdings Corp., KKR & Co. Inc., as the sole shareholder of KKR Group Holdings Corp., KKR Management LLC, as the Class B common stockholder of KKR & Co. Inc., and Messrs. Henry R. Kravis and George R. Roberts, as the designated members of KKR Management LLC, may be deemed to be the beneficial owners having shared voting and investment power with respect to the shares described above. Each of Messrs. Kravis and Roberts disclaims beneficial ownership of the shares held by KKR Genetic Disorder L.P."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein. The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the Reporting Persons are the beneficial owners of any securities reported herein."}],"balance_after":36900661,"source":{"system":"sec-edgar","filing":"0000899243-19-019173","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1081715/000089924319019173/doc4.xml","form_type":"4"}},{"id":401651,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":15085,"kind":"organization","name":"KKR Genetic Disorder L.P.","position":1,"cik":"0001780408","reported_name":"KKR Genetic Disorder L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":341,"kind":"person","name":"ROBERTS GEORGE R","position":2,"cik":"0001081715","reported_name":"ROBERTS GEORGE R","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":340,"kind":"person","name":"KRAVIS HENRY R","position":3,"cik":"0001081714","reported_name":"KRAVIS HENRY R","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":339,"kind":"organization","name":"KKR Management LLP","position":4,"cik":"0001472694","reported_name":"KKR Management LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":338,"kind":"organization","name":"KKR & Co. Inc.","symbol":"KKR","position":5,"cik":"0001404912","reported_name":"KKR & Co. Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":336,"kind":"organization","name":"KKR Group Holdings Corp.","position":6,"cik":"0001743754","reported_name":"KKR Group Holdings Corp.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15930,"kind":"organization","name":"KKR Management Holdings Corp","position":7,"cik":"0001472692","reported_name":"KKR Management Holdings Corp","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15931,"kind":"organization","name":"KKR Management Holdings L.P.","position":8,"cik":"0001472693","reported_name":"KKR Management Holdings L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15086,"kind":"organization","name":"KKR Genetic Disorder GP LLC","position":9,"cik":"0001780428","reported_name":"KKR Genetic Disorder GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-07-03T20:30:24.000Z","date":"2019-07-01","kind":"exercise","acquired":true,"shares":34253561,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering (the \"IPO\"), all Series B Preferred Units, Series C Preferred Units and Series D Preferred Units (collectively, the \"Preferred Units\") of BridgeBio Pharma LLC (the \"LLC\") were exchanged for shares of Common Stock, par value $0.001 per share (the \"Common Stock\"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the \"Reorganization\"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of Preferred Units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, with a value implied by the IPO price of $17.00 per share. The Preferred Units had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities of the Issuer are held by KKR Genetic Disorder L.P. KKR Genetic Disorder GP LLC, as the general partner of KKR Genetic Disorder L.P., KKR Management Holdings L.P., as the sole member of KKR Genetic Disorder GP LLC, KKR Management Holdings Corp., as the general partner of KKR Management Holdings L.P., KKR Group Holdings Corp., as the sole shareholder of KKR Management Holdings Corp., KKR & Co. Inc., as the sole shareholder of KKR Group Holdings Corp., KKR Management LLC, as the Class B common stockholder of KKR & Co. Inc., and Messrs. Henry R. Kravis and George R. Roberts, as the designated members of KKR Management LLC, may be deemed to be the beneficial owners having shared voting and investment power with respect to the shares described above. Each of Messrs. Kravis and Roberts disclaims beneficial ownership of the shares held by KKR Genetic Disorder L.P."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein. The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the Reporting Persons are the beneficial owners of any securities reported herein."}],"balance_after":34253561,"source":{"system":"sec-edgar","filing":"0000899243-19-019173","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1081715/000089924319019173/doc4.xml","form_type":"4"}}]}